Ziprasidone (mesylate)
CAT:
804-HY-14542C
Size:
1 Each
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ziprasidone (mesylate)
Description:
Ziprasidone (CP-88059) mesylate is an orally active combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone mesylate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) [1].Product Name Alternative:
CP-88059 (mesylate)UNSPSC:
12352005Hazard Statement:
H302-H315-H319-H335Target:
5-HT Receptor; Dopamine ReceptorType:
Reference compoundRelated Pathways:
GPCR/G Protein; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
Neurological DiseaseAssay Protocol:
https://www.medchemexpress.com/ziprasidone-mesylate.htmlSolubility:
10 mM in DMSOSmiles:
ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5.OS(=O)(C)=OMolecular Formula:
C22H25ClN4O4S2Molecular Weight:
509.04Precautions:
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501References & Citations:
[1]H Rollema, et al. 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48 (3) :229-37.|[2]Zhi Su, et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol. 2006 Jan 12;71 (3) :278-86.|[3]Subin Park, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012 Jun;61 (6) :787-93.Shipping Conditions:
Room temperatureScientific Category:
Reference compound1Clinical Information:
LaunchedIsoform:
5-HT1 Receptor;5-HT2 Receptor; D2 Receptor; mLAG-3; α-1 microglobulinCAS Number:
185021-64-1
